Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 2, 2014, Pages 281-289

  Lin, Liyan ^a   Wei, Juanbing ^a   Chen, Yuqing ^a   Huang, Aimin ^a   Li, Kay Ka Wai ^b   Zhang, Wenmin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dendritic cells; Immunotherapy; Lentivirus vector; Melanoma antigen gene A3; Tumor

Indexed keywords

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; LIVER NEOPLASMS; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; T-LYMPHOCYTES;

EID: 84895075017     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1552-8     Document Type: Article

References (41)

1. Adotevi O, Mollier K, Neuveut C, Dosset M, Ravel P, Fridman WH, Tartour E, Charneau P, Wain-Hobson S, Langlade-Demoyen P (2010) Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 115(15):3025-3032
2. Arce F, Breckpot K, Collins M, Escors D (2011) Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev 7(4):248-260
3. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kroger N (2007) Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109(3):1103-1112
4. Bellati F, Napoletano C, Tarquini E, Palaia I, Landi R, Manci N, Spagnoli G, Rughetti A, Panici PB, Nuti M (2007) Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur J Cancer 43(17):2621-2627
5. Bhargava A, Mishra D, Banerjee S, Mishra PK (2012) Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation. Immunotherapy 4(7):703-718
6. Boudreau JE, Bonehill A, Thielemans K, Wan Y (2011) Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 19(5):841-853
7. Carrasco J, Van Pel A, Neyns B, Lethe B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D (2008) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180(5):3585-3593
8. Cui J, Lin AL, Liu Q, Sun Q, Gao ZH (2010) Dendritic cells transfected with lentiviral vector-encoding human granulocyte-macrophage colony-stimulating factor augment anti-tumour T-cell response in vitro. Int J Immunogenet 37(5):329-336
9. Dasgupta A, McCarty D, Spencer HT (2010) Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge. Biochem Biophys Res Commun 391(1):170-175
10. Decker T, Lohmann-Matthes ML (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115(1):61-69
11. Hemminger JA, Ewart Toland A, Scharschmidt TJ, Mayerson JL, Kraybill WG, Guttridge DC, Iwenofu OH (2013) The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol 26(2):282-288
12. Hu B, Dai B, Wang P (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28(41):6675-6683
13. Hussein YM, Ghareib AF, Mohamed RH, Radwan MI, Elsawy WH (2012) MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma. Med Oncol 29(2):994-999
14. Jung EJ, Kim MA, Lee HS, Yang HK, Lee YM, Lee BL, Kim WH (2005) Expression of family a melanoma antigen in human gastric carcinoma. Anticancer Res 25(3B):2105-2111
15. Kealy B, Liew A, McMahon JM, Ritter T, O'Doherty A, Hoare M, Greiser U, Vaughan EE, Maenz M, O'Shea C, Barry F, O'Brien T (2009) Comparison of viral and nonviral vectors for gene transfer to human endothelial progenitor cells. Tissue Eng Part C Methods 15(2):223-231
16. Korzeniewski C, Callewaert DM (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64(3):313-320
17. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31(19):2413-2420
18. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, Gu J (2005) Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 11(5):1809-1814
19. Li DY, Gu C, Min J, Chu ZH, Ou QJ (2012) Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp Ther Med 4(1):131-134
20. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295(5556):868-872
21. Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, Zannini P, Traversari C (2004) Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 12(1):145-151
22. Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM, Parmiani G (1997) Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57(24):5534-5541
23. Negri DR, Michelini Z, Bona R, Blasi M, Filati P, Leone P, Rossi A, Franco M, Cara A (2011) Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther 11(6):739-750
24. Ohman Forslund K, Nordqvist K (2001) The melanoma antigen genes - any clues to their functions in normal tissues? Exp Cell Res 265(2):185-194
25. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N, Yamamoto A, Takesako K, Yamaguchi K, Akiyama Y (2012) Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 28(4):1131-1138
26. Peled N, Oton AB, Hirsch FR, Bunn P (2009) MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy 1(1):19-25
27. Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, Wei L, Leng XS, Wang Y, Chen WF (2005) Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219(2):223-232
28. Pincha M, Sundarasetty BS, Salguero G, Gutzmer R, Garritsen H, Macke L, Schneider A, Lenz D, Figueiredo C, Blasczyk R, Ruggiero E, Schmidt M, von Kalle C, Puff C, Modlich U, von der Leyen H, Wicke DC, Ganser A, Stripecke R (2012) Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. Hum Gene Ther Methods 23(1):38-55
29. Rossetti M, Cavarelli M, Gregori S, Scarlatti G (2013) HIV-derived vectors for gene therapy targeting dendritic cells. Adv Exp Med Biol 762:239-261
30. Rossi M, Young JW (2005) Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 175(3):1373-1381
31. Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchiano A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M (2013) Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer 132(11):2557-2566
32. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32
33. Tanaka FHN, Isikawa K, Inoue H, Mori M (2008) Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep 20(25):1111-1116
34. Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S (2009) Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol 183(7):4800-4808
35. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643-1647
36. Vogel TU, Visan L, Ljutic B, Gajewska B, Caterini J, Salha D, Wen T, He L, Parrington M, Cao SX, McNeil B, Sandhu D, Scollard N, Zhang L, Bradley B, Tang M, Lovitt C, Oomen R, Dunn P, Tartaglia J, Berinstein NL (2010) Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother 33(8):743-758
37. Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE (2012) Induction of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 34(12):1734-1746
38. Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34(5):448-456
39. Wojas-Krawczyk K, Krawczyk P, Buczkowski J, Walkowska A, Jankowska O, Czekajska-Chehab E, Milanowski J (2012) Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report. Arch Immunol Ther Exp (Warsz) 60(1):69-77
40. Xiao L, Kim J, Lim M, Dai B, Yang L, Reed SG, Baltimore D, Wang P (2012) A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses. Vaccine 30(15):2570-2581
41. Xie LH, Sin FW, Cheng SC, Cheung YK, Chan KT, Xie Y (2008) Activation of cytotoxic T lymphocytes against CML28-bearing tumors by dendritic cells transduced with a recombinant adeno-associated virus encoding the CML28 gene. Cancer Immunol Immunother 57(7):1029-1038